Our work is entirely funded by private donations – we receive no money from government. Your money will help us continue funding research into vitiligo and supporting people affected by the condition.
Deucravacitinib for nonsegmental vitiligo
Official title: Vitiligo Treatment by Targeting TYK2 Mediated Responses Prospective Multicentric Double Blind Interventional Study
Status: Closed to new participants
Description:
Centre Hospitalier Universitaire de Nice plans to enroll about 128 participants. Deucravacitinib blocks TYK2, an immune enzyme involved in inflammatory signaling. Researchers hope it will reduce the immune attack on melanocytes and improve skin color. Deucravacitinib is sold as Sotyktu and is approved for plaque psoriasis; vitiligo would be a new use. Possible effects include respiratory infections, headache, acne, and mouth sores. People ages 18 to 75 may qualify. The study is underway but is no longer accepting new participants.
Start date: May 05, 2024
Completion date: July 05, 2027
Organizer: Centre Hospitalier Universitaire de Nice
Contact: PASSERON Thierry, PhD
Clinical Trial Alerts
Sign up and be the first to know about updates on this trial.
FAQOther Questions
- Can Ginkgo Biloba help with vitiligo?
Ginkgo Biloba offers a promising, simple, and relatively affordable option for managing vitiligo. Known for its anti-inflammatory, immunomodulatory, and antioxidant properties, ...
- Is it possible to stop the progression of vitiligo?
While it's not always possible to quickly stop vitiligo progression, there are some treatments that can help slow or halt the spread of the condition in many cases: Corticostero...
- Is it Bitiligo? Vitaligo? Veteligo?
There are so many different ways that people try and spell or even pronounce Vitiligo. Here are some common mis-spellings: bitiligo, vitigo, vitaligo, vitilago, vitiglio, vitag...
Though it is not always easy to treat vitiligo, there is much to be gained by clearly understanding the diagnosis, the future implications, treatment options and their outcomes.
Many people deal with vitiligo while remaining in the public eye, maintaining a positive outlook, and having a successful career.
Copyright (C) Bodolóczki JúliaBy taking a little time to fill in the anonymous questionnaire, you can help researchers better understand and fight vitiligo.